ArticleBioinformatics advances2023
Prediction of antibody binding to SARS-CoV-2 RBDs.
Article in Bioinformatics advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Generative prediction of real-world prevalent SARS-CoV-2 mutation with in silico virus evolution.Briefings in bioinformatics · 2025Article
- Biophysics of SARS-CoV-2 spike protein's receptor-binding domain interaction with ACE2 and neutralizing antibodies: from computation to functional insights.Biophysical reviews · 2025Review
- Article
- NABP-BERT: NANOBODY®-antigen binding prediction based on bidirectional encoder representations from transformers (BERT) architecture.Briefings in bioinformatics · 2024Article
- Exploring the ability of the MD+FoldX method to predict SARS-CoV-2 antibody escape mutations using large-scale data.Scientific reports · 2024Article
- Exploring the ability of the MD+FoldX method to predict SARS-CoV-2 antibody escape mutations using large-scale data.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Summary: The ability to predict antibody-antigen binding is essential for computational models of antibody affinity maturation and protein design. While most models aim to predict binding for arbitrary antigens and antibodies, the global impact of SARS-CoV-2 on public health and the availability of associated data suggest that a SARS-CoV-2-specific model would be highly beneficial. In this work, we present a neural network model, trained on ∼315 000 datapoints from deep mutational scanning experiments, that predicts escape fractions of SARS-CoV-2 RBDs binding to arbitrary antibodies. The antibody embeddings within the model constitute an effective sequence space, which correlates with the Hamming distance, suggesting that these embeddings may be useful for downstream tasks such as binding prediction. Indeed, the model achieves Spearman correlation coefficients of 0.46 and 0.52 on two held-out test sets. By comparison, correlation coefficients calculated using existing structure and sequence-based models do not exceed 0.28. The correlation coefficient against dissociation constants of antibodies binding to SARS-CoV-2 RBD variants is 0.46. Additionally, the residue-level escapes are highest in the antibody epitope, correlating well with experimentally measured escapes. We further study the effect of antibody chain use, embedding dimension size and feed-forward and convolutional architectures on the model results. Lastly, we find that the inference time of our model is significantly faster than previous models, suggesting that it could be a useful tool for the accurate and rapid prediction of antibodies binding to SARS-CoV-2 RBDs. Availability and implementation: The model and associated code are available for download at https://github.com/ericzwang/RBD_AB. Supplementary information: Supplementary data are available at
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.